ABVC News and Press, ABVC BioPharma Inc. From 05/12/22

Fremont, CA - ( NewMediaWire ) - May 12, 2022 - ABVC BioPharma, Inc. (“ABVC” or the “Company”) (NASDAQ: ABVC) today announced that it has entered into securities purchase agreements with certain institutional investors for the issuance and sale of 2,000,000 sh...

Fremont, CA - ( NewMediaWire ) - May 10, 2022 - ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the first subject began treatment at the Cheng Hsin General Ho...

New Process Improves Quality and Lowers Cost   Fremont, CA - ( NewMediaWire ) - May 05, 2022 - ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Vi...

New Process Improves Quality and Lowers Cost Fremont, CA, May 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology...

ABVC Biopharma (NASDAQ:ABVC) has announced that BioKey, a wholly-owned subsidiary of the Co., has entered into a $3M clinical services contract with NeuCen BioMed. The contract will guide two NeuCen drug products, CEN501 and NEU001, through completion of Phase II clinical studies under U.S. F...

Fremont, CA - ( NewMediaWire ) - May 03, 2022 - ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that BioKey, a wholly-owned subsidiary of the company based in Frem...

Fremont, CA - ( NewMediaWire ) - April 28, 2022 - ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that all five clinical study sites in Taiwan participating in the...

FREMONT, CA - ( NewMediaWire ) - April 26, 2022 - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the principal investigators of the Phase II clinical study o...

ABVC BioPharma press release (NASDAQ:ABVC): FY net loss of $12.03M Revenue of $355.79M (-26.3% Y/Y). For further details see: ABVC BioPharma reports FY results

Fremont, CA - ( NewMediaWire ) - March 31, 2022 - ABVC BioPharma, Inc. (Nasdaq: ABVC), a biotechnology company specializing in botanically based solutions that seeks to deliver high efficacy with low toxicity for improved health outcomes, today announced its financial and operating results for...